Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

The impact of microgravity on cancer development and treatment

The Wake Forest Institute for Regenerative Medicine (WFIRM) is honored to announce its selection for a pioneering cancer research project that will take place aboard the International Space Station (ISS). The project, one of only five chosen through a competitive solicitation by the ISS National Lab in partnership with NASA, aims to explore the effects of microgravity on cancer development and treatment.

6 Sep 2024

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics.

5 Sep 2024

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

From ERS Genomics 5 Sep 2024

Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders

Misha Kudryshev's lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia.

4 Sep 2024

Study shows how troriluzole can target early-stage alterations associated with Alzheimer's

In a recent development in Alzheimer's disease research, Auburn University scientists have studied a new drug, troriluzole, that can prevent brain changes leading to memory loss and cognitive decline in a mouse model of the disease.

3 Sep 2024

NSF AIRFoundry to advance RNA technology and nanoparticle design

In a typical foundry, raw materials like steel and copper are melted down and poured into molds to assume new shapes and functions.

3 Sep 2024

Sapio Sciences advances the world's first AI-powered lab assistant

Sapio ELaiN couples AI and natural language processing to deliver the future interface for scientists and lab operations.

From Sapio Sciences 3 Sep 2024

New method accelerates drug discovery from years to months

Researchers from the University of Cincinnati College of Medicine and Cincinnati Children's Hospital have found a new method to increase both speed and success rates in drug discovery.

30 Aug 2024

Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development

Advances in tissue engineering and 3D bioprinting have revolutionized the development of physiologically relevant 3D in vitro cancer models, offering a closer representation of the tumor microenvironment (TME) and enabling high-throughput drug screening.

From Carcinotech 30 Aug 2024

Carcinotech dominates summer awards season

Over the past six years, Carcinotech has been laser-focused on developing, optimising and commercializing our innovative drug development platform.

From Carcinotech 30 Aug 2024

Study reveals the role of blood clotting in COVID-19

In a study that reshapes what we know about COVID-19 and its most perplexing symptoms, scientists have discovered that the blood coagulation protein fibrin causes the unusual clotting and inflammation that have become hallmarks of the disease, while also suppressing the body's ability to clear the virus.

29 Aug 2024

Study introduces a novel approach to mapping protein-receptor interactions

One in every three FDA-approved drugs targets a single superfamily of receptors dotting the surfaces of human cells.

28 Aug 2024

Cell therapy commercialization: Streamline your path to cell therapy commercialization

Moving your cell therapy clinical trial beyond Phase I is an exciting time, marking a significant milestone. There are many therapeutic developers working to address critical patient needs in oncology, auto-immune, regenerative medicine, and other spaces.

From Charles Rivers Laboratories Cell and Gene Therapy 28 Aug 2024

SciY and Allchemy announce strategic distribution agreement

SciY is proud to announce a strategic distribution agreement with Allchemy, a pioneer in Artificial Intelligence (AI) driven drug discovery, co-founded by renowned experts Dr. Sara Szymkuć and Prof. Bartosz Grzybowski.

From SciY 28 Aug 2024

EPAM Joins Sapio Sciences Partner Program

...

From Sapio Sciences 27 Aug 2024

New method uncovers hidden cancer targets

Fighting cancer effectively often involves stopping cancer cells from multiplying, which requires understanding the proteins that the cells rely on to survive.

27 Aug 2024

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

Austocystin D, a natural compound produced by fungi, has been recognized for its cytotoxic effects and anticancer activity in various cell types. It exhibits potent activity even in cells that express proteins associated with multidrug resistance, attracting significant global research interest.

27 Aug 2024

Drug Discovery News and Research

Further Reading

The impact of microgravity on cancer development and treatment

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Novel intermediate form of serotonin receptor identified as therapeutic target for psychiatric disorders

Study shows how troriluzole can target early-stage alterations associated with Alzheimer's

NSF AIRFoundry to advance RNA technology and nanoparticle design

Sapio Sciences advances the world's first AI-powered lab assistant

New method accelerates drug discovery from years to months

Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development

Carcinotech dominates summer awards season

Study reveals the role of blood clotting in COVID-19

Study introduces a novel approach to mapping protein-receptor interactions

Cell therapy commercialization: Streamline your path to cell therapy commercialization

SciY and Allchemy announce strategic distribution agreement

EPAM Joins Sapio Sciences Partner Program

New method uncovers hidden cancer targets

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

University of Oklahoma researcher receives NIH grant to explore natural cancer treatments

Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors

Wake Forest Institute for Regenerative Medicine joins new NSF-funded pandemic prediction initiative

Binding kinetics in drug discovery eBook eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery